Business Wire

ROKA and IRONMAN Expand Relationship with Global Partnership

Jaa

IRONMAN, a Wanda Sports Holdings company, announced today a multi-year global partnership that expands its relationship with ROKA, the Austin-based performance multisport brand. This new partnership makes ROKA the Official Global Wetsuit and Swim Partner of IRONMAN® and the IRONMAN World Championship and IRONMAN 70.3® World Championship events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180531006432/en/

The most inspiring swim start in all of triathlon. #FindFaster #IMKona (Photo: Business Wire)

The most inspiring swim start in all of triathlon. #FindFaster #IMKona (Photo: Business Wire)

The partnership between IRONMAN and ROKA will further a relationship that began in 2014. Besides an expanded physical presence at IRONMAN events across the globe, ROKA and IRONMAN are collaborating on IRONMAN World Championship swim products this October in honor of IRONMAN’s 40th Anniversary. Additionally, ROKA will now sell co-branded swim products online via www.ironmanstore.com and roka.com, and will continue to give out the ROKA Fastest Swimmer Award to congratulate the fastest age group athlete during each event’s swim.

“We’re thrilled to expand our partnership with IRONMAN,” said ROKA CEO and Co-Founder Rob Canales. “IRONMAN is the best in the world at providing the ultimate endurance race experience, and ROKA is the best in the world at supporting those athletes with technical products that meet the demands of the day. We’re excited to collaborate with IRONMAN on new products and services and to immediately bring our existing ones to more athletes around the world.”

In the last six years, ROKA has designed the world’s most advanced high-performance wetsuits, goggles, eyewear, swimskins and race apparel, which have been worn to numerous world titles and over 50 IRONMAN and IRONMAN 70.3 wins by the world’s best triathletes, including Javier Gómez Noya, Lucy Charles, Tim Reed, Melissa Hauschildt, Luke McKenzie, Meredith Kessler, Linsey Corbin, Jesse Thomas and more. With this new partnership, IRONMAN athletes will be able to sample ROKA’s groundbreaking technology before they buy at each IRONMAN event in the IRONMAN Village and have exclusive access to new products during the lead up to their races.

“I first tried ROKA’s Maverick wetsuit and Viper swimskin in 2014 and have been using both ever since, however the products have at times been difficult to find outside the U.S.” said Javier Gómez Noya, two-time IRONMAN 70.3 World Champion who splits time between Spain and New Zealand. “With this expanded partnership, IRONMAN athletes from around the globe can now get their hands on the cutting-edge technology that has been my secret weapon for the past four years.”

Just six years from its humble beginnings in a garage in Austin, ROKA has grown to become the wetsuit and swimwear choice of countless triathletes and hundreds of multisport teams around the world, and its Viper swimskin has been trusted by more athletes at the IRONMAN World Championships than any other brand for multiple years running.

“ROKA embodies the spirit of innovation and ingenuity that aligns well with the needs of our athletes,” said Matthieu Van Veen, Chief Revenue Officer for IRONMAN. “We are eager to expand this partnership to cover all of our events globally and bring ROKA’s swimwear products to our athletes around the world.”

In 2018, ROKA will have a presence across the IRONMAN® and IRONMAN 70.3® Series, including 40 races in North America, 32 in Europe, and 13 in Oceania, as well as the IRONMAN World Championship and IRONMAN 70.3 World Championship. Each IRONMAN race consists of a 2.4-mile swim, 112-mile bike and 26.2-mile run while the IRONMAN 70.3 race series events consist of a 1.2-mile swim, 56-mile bike and 13.1-mile run.

For more information on the IRONMAN brand and global event series, visit www.ironman.com.

Find out more about ROKA at roka.com.

About ROKA

ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. ROKA’s mission is to unlock human potential. To equip, empower, inspire and ignite. ROKA serves those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be.

Since its launch in 2013, ROKA athletes have won over a dozen world titles and have been instrumental in the design and development of an unprecedented collection of patented and award-winning products. In 2016, ROKA was proud to send 18 athletes to the Rio Olympics, taking home Gold and Bronze. In PyeongChang, ROKA continued the tradition, taking home Olympic Gold and Bronze in their Advanced Performance eyewear. 2018 has seen elite athletes around the globe in running, cycling, triathlon, speed skating, beach volleyball, and off-road endurance events trusting ROKA eyewear for their most important performances on the biggest of stages.

ROKA products are available worldwide at www.roka.com and through select retailers. Visit us online to learn more about our growing lines of premium performance eyewear. Follow ROKA on social media at Facebook, Twitter, and Instagram.

About IRONMAN

A Wanda Sports Holdings company, IRONMAN operates a global portfolio of events that includes the IRONMAN® Triathlon Series, the IRONMAN® 70.3® Triathlon Series, 5150™ Triathlon Series, the Rock n’ Roll Marathon Series®, Iron Girl®, IRONKIDS®, International Triathlon Union World Triathlon Series races, road cycling events including the UCI Velothon® Series, mountain bike races including the Absa Cape Epic®, premier marathons including the Standard Chartered Singapore Marathon, and other multisport races. IRONMAN’s events, together with all other Wanda Sports Holdings events, provide more than a million participants annually the benefits of endurance sports through the company’s vast offerings. The iconic IRONMAN® Series of events is the largest participation sports platform in the world. Since the inception of the IRONMAN® brand in 1978, athletes have proven that ANYTHING IS POSSIBLE® by crossing finish lines at the world’s most challenging endurance races. Beginning as a single race, IRONMAN has grown to become a global sensation with more than 200 events across 50 countries. For more information, visit www.ironman.com.

About Wanda Sports Holdings

Wanda Sports Holdings is the world’s leading sports business entity, founded to capture the opportunities in the global sports industry and to contribute to the prosperous international sports landscape – in three key areas: 1) Spectator Sports (media and marketing business), 2) Participation Sports (active lifestyle business), 3) Services (digital, production and service business). Wanda Sports Holding incorporates the international sports marketing company Infront Sports & Media, the iconic endurance brand IRONMAN, and Wanda Sports China. The headquarters are in Guangzhou, China.

Contact information

ROKA
Editorial contact
Diane Thibert
VP Communications & Public Relations
(310) 804-2400 / diane@roka.com
or
IRONMAN
Dan Berglund
Director of Communications
Press@ironman.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme